Viridian Therapeutics Announces Pricing of Public Offering of Shares of Common Stock
17 Enero 2024 - 9:00PM
Business Wire
Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology
company focused on discovering and developing potential
best-in-class medicines for serious and rare diseases, today
announced the pricing of an underwritten public offering with gross
proceeds of approximately $150.0 million. Viridian is selling a
total of 7,142,858 shares of common stock at a public offering
price of $21.00 per share. In addition, Viridian has granted the
underwriters a 30-day option to purchase an additional 1,071,428
shares of common stock at the public offering price, less
underwriting discounts and commissions.
All of the shares to be sold in the underwritten public offering
are being offered by Viridian. The offering is expected to close on
or about January 22, 2024, subject to customary closing
conditions.
Viridian intends to use the proceeds from the proposed
underwritten public offering of its shares of common stock,
together with its cash, cash equivalents and short-term
investments, to further its clinical development programs, as well
as for working capital and general corporate purposes.
Jefferies and Leerink Partners are acting as joint lead
book-running managers for the offering.
A registration statement relating to these securities has been
filed with the Securities and Exchange Commission (SEC) and became
effective on September 9, 2022. A final prospectus supplement
relating to and describing the terms of the offering will be filed
with the SEC. The securities described above have not been
qualified under any state blue sky laws. This press release shall
not constitute an offer to sell or the solicitation of an offer to
buy these securities, nor shall there be any sale of these
securities in any state or other jurisdiction in which such offer,
solicitation or sale would be unlawful prior to the registration or
qualification under the securities laws of any such state or other
jurisdiction. The offering can be made only by means of a
prospectus, copies of which may be obtained at the SEC’s website at
www.sec.gov, or by request to Jefferies LLC (Attention: Equity
Syndicate Prospectus Department, 520 Madison Avenue, New York, New
York 10022; telephone: 877-821-7388; email:
Prospectus_Department@Jefferies.com) or Leerink Partners LLC,
Attention: Syndicate Department, 53 State Street, 40th Floor,
Boston, MA 02109, by telephone at (800) 808-7525, ext. 6105, or by
email at syndicate@leerink.com.
About Viridian Therapeutics, Inc.
Viridian is a biopharmaceutical company focused on engineering
and developing potential best-in-class medicines for patients with
serious and rare diseases. Viridian’s expertise in antibody
discovery and engineering enables it to develop differentiated
therapeutic candidates for previously validated drug targets in
commercially established disease areas.
Viridian is advancing multiple candidates in the clinic for the
treatment of patients with thyroid eye disease (TED). The company
is conducting two global Phase 3 clinical trials (THRIVE and
THRIVE-2) to evaluate the safety and efficacy of VRDN-001 in
patients with active and chronic TED. Viridian’s goal is to advance
VRDN-001 as a best-in-class IV therapy followed by VRDN-003 as a
first- and best-in-class subcutaneous therapy for the treatment of
TED. In addition to its TED portfolio, Viridian is advancing a
novel portfolio of neonatal Fc receptor (FcRn) inhibitors, VRDN-006
and VRDN-008, which has the potential to be developed in multiple
autoimmune diseases.
Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. These statements may be identified by the use of words such
as, but not limited to, “anticipate,” “believe,” “continue,”
“could,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,”
“potential,” “predict,” “project,” “should,” “target,” “will,” or
“would” or other similar terms or expressions that concern the
company’s expectations, plans and intentions. Forward-looking
statements include, without limitation, statements regarding the
underwritten public offering and the company’s expectations with
respect to the use of the net proceeds from the underwritten public
offering. Forward-looking statements are neither historical facts
nor assurances of future performance. Instead, they are based on
the company’s current beliefs, expectations and assumptions. New
risks and uncertainties may emerge from time to time, and it is not
possible to predict all risks and uncertainties. No representations
or warranties (expressed or implied) are made about the accuracy of
any such forward-looking statements. Such forward-looking
statements are subject to a number of material risks and
uncertainties including but not limited to: the satisfaction of
customary closing conditions related to the underwritten public
offering; and other risks and uncertainties identified in the
company’s filings with the SEC, including those risks set forth
under the caption “Risk Factors” in the company’s Quarterly Report
on Form 10-Q filed with the SEC on November 13, 2023 and other
subsequent disclosure documents filed with the SEC. Any
forward-looking statement speaks only as of the date on which it
was made. Neither the company, nor its affiliates, advisors or
representatives, undertake any obligation to publicly update or
revise any forward-looking statement, whether as a result of new
information, future events or otherwise, except as required by law.
These forward-looking statements should not be relied upon as
representing the company’s views as of any date subsequent to the
date hereof.
Source: Viridian Therapeutics, Inc.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240117318433/en/
Investor & Media Contact: Louisa Stone, 617-272-4604
Manager, Investor Relations IR@viridiantherapeutics.com
Viridian Therapeutics (NASDAQ:VRDN)
Gráfica de Acción Histórica
De Ago 2024 a Sep 2024
Viridian Therapeutics (NASDAQ:VRDN)
Gráfica de Acción Histórica
De Sep 2023 a Sep 2024